SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-18-001749
Filing Date
2018-02-06
Accepted
2018-02-06 06:04:13
Documents
46
Period of Report
2017-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q avir20171231_10q.htm 10-Q 600285
2 EXHIBIT 31.1 ex_103756.htm EX-31.1 16672
3 EXHIBIT 31.2 ex_103757.htm EX-31.2 16825
4 EXHIBIT 32.1 ex_103758.htm EX-32.1 12813
  Complete submission text file 0001437749-18-001749.txt   2643103

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT avir-20171231.xml EX-101.INS 489978
6 XBRL TAXONOMY EXTENSION SCHEMA avir-20171231.xsd EX-101.SCH 32446
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE avir-20171231_cal.xml EX-101.CAL 27250
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE avir-20171231_def.xml EX-101.DEF 181407
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20171231_lab.xml EX-101.LAB 152875
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20171231_pre.xml EX-101.PRE 195947
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Filer) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-35285 | Film No.: 18576141
SIC: 2836 Biological Products, (No Diagnostic Substances)